bumetanide has been researched along with Stroke in 9 studies
Stroke: A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Total seizure burden varied widely, with much higher seizure burden in treatment versus control groups (median = 3." | 7.01 | A Pilot Randomized, Controlled, Double-Blind Trial of Bumetanide to Treat Neonatal Seizures. ( Bergin, AM; Dong, M; Fortuno, CR; Hayes, B; Jensen, FE; Krishnamoorthy, K; O'Reilly, D; Rofeberg, V; Singh, A; Soul, JS; Staley, KJ; Stopp, C; Vinks, AA; Wypij, D, 2021) |
| "Bumetanide is a specific Na+-K+-Cl- co-transporter inhibitor which can maintain chloride homeostasis in neurons." | 6.61 | Bumetanide: A review of its neuroplasticity and behavioral effects after stroke. ( Liu, F; Qu, H; Sun, X; Tao, D; Xiao, T; Zhao, C; Zhao, M; Zhao, S; Zhou, Z, 2019) |
| "These data suggest that bumetanide exerts its neuroprotective and anti-edema effects partly via blockade of the perivascular pool of AQP4 and may have therapeutic potential for ischemic stroke in the clinical setting." | 3.76 | Na(+)-K (+)-2Cl (-) cotransport inhibitor attenuates cerebral edema following experimental stroke via the perivascular pool of aquaporin-4. ( Adams, ME; Amiry-Moghaddam, M; Bhardwaj, A; Froehner, SC; Migliati, ER; Ottersen, OP, 2010) |
| "Total seizure burden varied widely, with much higher seizure burden in treatment versus control groups (median = 3." | 3.01 | A Pilot Randomized, Controlled, Double-Blind Trial of Bumetanide to Treat Neonatal Seizures. ( Bergin, AM; Dong, M; Fortuno, CR; Hayes, B; Jensen, FE; Krishnamoorthy, K; O'Reilly, D; Rofeberg, V; Singh, A; Soul, JS; Staley, KJ; Stopp, C; Vinks, AA; Wypij, D, 2021) |
| "Neonatal stroke is the second cause of acute symptomatic neonatal seizures after hypoxic-ischemic encephalopathy." | 2.82 | Efficacy of the anti-seizure medications in acute symptomatic neonatal seizures caused by stroke. A systematic review. ( Criscione, R; Falsaperla, R; Marino, S; Pisani, F; Praticò, A; Ruggieri, M; Sortino, V, 2022) |
| "Bumetanide is a specific Na+-K+-Cl- co-transporter inhibitor which can maintain chloride homeostasis in neurons." | 2.61 | Bumetanide: A review of its neuroplasticity and behavioral effects after stroke. ( Liu, F; Qu, H; Sun, X; Tao, D; Xiao, T; Zhao, C; Zhao, M; Zhao, S; Zhou, Z, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 3 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Tóth, K | 1 |
| Lénárt, N | 1 |
| Berki, P | 1 |
| Fekete, R | 1 |
| Szabadits, E | 1 |
| Pósfai, B | 1 |
| Cserép, C | 1 |
| Alatshan, A | 1 |
| Benkő, S | 1 |
| Kiss, D | 1 |
| Hübner, CA | 1 |
| Gulyás, A | 1 |
| Kaila, K | 1 |
| Környei, Z | 1 |
| Dénes, Á | 1 |
| Sortino, V | 1 |
| Praticò, A | 1 |
| Marino, S | 1 |
| Criscione, R | 1 |
| Ruggieri, M | 1 |
| Pisani, F | 1 |
| Falsaperla, R | 1 |
| Soul, JS | 1 |
| Bergin, AM | 1 |
| Stopp, C | 1 |
| Hayes, B | 1 |
| Singh, A | 1 |
| Fortuno, CR | 1 |
| O'Reilly, D | 1 |
| Krishnamoorthy, K | 1 |
| Jensen, FE | 1 |
| Rofeberg, V | 1 |
| Dong, M | 1 |
| Vinks, AA | 1 |
| Wypij, D | 1 |
| Staley, KJ | 1 |
| Tao, D | 1 |
| Liu, F | 1 |
| Sun, X | 1 |
| Qu, H | 1 |
| Zhao, S | 1 |
| Zhou, Z | 1 |
| Xiao, T | 1 |
| Zhao, C | 2 |
| Zhao, M | 1 |
| Yamagata, K | 1 |
| Yamamoto, M | 1 |
| Kawakami, K | 1 |
| Ohara, H | 1 |
| Nabika, T | 1 |
| Xu, W | 1 |
| Mu, X | 1 |
| Wang, H | 1 |
| Song, C | 1 |
| Ma, W | 1 |
| Jolkkonen, J | 1 |
| O'Donnell, ME | 2 |
| Lam, TI | 1 |
| Tran, L | 1 |
| Anderson, SE | 1 |
| Migliati, ER | 1 |
| Amiry-Moghaddam, M | 1 |
| Froehner, SC | 1 |
| Adams, ME | 1 |
| Ottersen, OP | 1 |
| Bhardwaj, A | 1 |
| Wallace, BK | 1 |
| Jelks, KA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Conivaptan for the Reduction of Cerebral Edema in Intracerebral Hemorrhage- A Safety and Tolerability Study[NCT03000283] | Phase 1 | 7 participants (Actual) | Interventional | 2017-03-22 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Changes in cerebral edema (CE) as measured on CT. Goal is a -5 to -10% change in CE over time. Change will be measured both as absolute change in volume, calculated as the final volume minus the baseline volume measure and converted to a percentage of the baseline volume measure. (NCT03000283)
Timeframe: Baseline to 168 hours post-enrollment
| Intervention | percentage of change from baseline (Mean) |
|---|---|
| Conivaptan Treatment Group | -37.1 |
Cost as measured by length of stay in the neuro ICU. (NCT03000283)
Timeframe: Enrollment through hospital discharge, up to 3 weeks
| Intervention | days (Mean) |
|---|---|
| Conivaptan Treatment Group | 14.4 |
All-cause deaths during hospitalization (NCT03000283)
Timeframe: Enrollment through hospital discharge, up to 3 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Conivaptan Treatment Group | 0 |
Modified Rankin Scale (0 to 6) at discharge from the hospital. A score of 0 indicates no disability and a score of 6 indicates the patient died. Functional independence is defined as a score of 2 or less. (NCT03000283)
Timeframe: At discharge from ICU and from hospital, up to 3 weeks
| Intervention | score on a scale (Median) |
|---|---|
| Conivaptan Treatment Group | 5 |
"Cost as measured by:~Need for external ventricular drain (EVD)/bolt or surgical procedures (craniectomy, clot evacuation,VPS) for reduction/management of CE.~Need for central venous lines, arterial lines, peripherally inserted central venous catheter (PICC) lines, tracheostomy/percutaneous endoscopic gastrostomies (PEGs).~Number of patients requiring a ventilator." (NCT03000283)
Timeframe: Baseline to 168 hours post-enrollment
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| EVD/bolt or surgical procedures | Lines or tracheostomy/PEG | Ventilator | |
| Conivaptan Treatment Group | 0 | 7 | 1 |
The number of participants with abnormal seizure activity and/or abnormal lab values and/or increase in infection rate and/or any drug-related adverse events. (NCT03000283)
Timeframe: Baseline to 168 hours post-enrollment
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Abnormal Seizure Activity | Abnormal Lab Values | Infections | Drug-related Adverse Events | |
| Conivaptan Treatment Group | 0 | 0 | 1 | 0 |
2 reviews available for bumetanide and Stroke
| Article | Year |
|---|---|
Efficacy of the anti-seizure medications in acute symptomatic neonatal seizures caused by stroke. A systematic review.
Topics: Anticonvulsants; Bumetanide; Epilepsy; Humans; Infant, Newborn; Infant, Newborn, Diseases; Levetirac | 2022 |
Bumetanide: A review of its neuroplasticity and behavioral effects after stroke.
Topics: Animals; Bumetanide; Humans; Neuronal Plasticity; Neurons; Recovery of Function; Sodium Potassium Ch | 2019 |
1 trial available for bumetanide and Stroke
| Article | Year |
|---|---|
A Pilot Randomized, Controlled, Double-Blind Trial of Bumetanide to Treat Neonatal Seizures.
Topics: Anticonvulsants; Bumetanide; Double-Blind Method; Drug Therapy, Combination; Electroencephalography; | 2021 |
6 other studies available for bumetanide and Stroke
| Article | Year |
|---|---|
The NKCC1 ion transporter modulates microglial phenotype and inflammatory response to brain injury in a cell-autonomous manner.
Topics: Animals; Brain Edema; Brain Injuries; Bumetanide; Embryo, Mammalian; Gene Expression Regulation; Hip | 2022 |
Arginine vasopressin regulated ASCT1 expression in astrocytes from stroke-prone spontaneously hypertensive rats and congenic SHRpch1_18 rats.
Topics: Amino Acid Transport System ASC; Animals; Arginine Vasopressin; Astrocytes; Brain; Bumetanide; Cell | 2014 |
Chloride Co-transporter NKCC1 Inhibitor Bumetanide Enhances Neurogenesis and Behavioral Recovery in Rats After Experimental Stroke.
Topics: Animals; Antigens, Nuclear; Behavior, Animal; Brain Infarction; Bromodeoxyuridine; Bumetanide; Cell | 2017 |
The role of the blood-brain barrier Na-K-2Cl cotransporter in stroke.
Topics: Animals; Astrocytes; Blood-Brain Barrier; Brain Edema; Brain Ischemia; Bumetanide; Cerebral Infarcti | 2004 |
Na(+)-K (+)-2Cl (-) cotransport inhibitor attenuates cerebral edema following experimental stroke via the perivascular pool of aquaporin-4.
Topics: alpha-Synuclein; Animals; Aquaporin 4; Brain Edema; Bumetanide; Cerebral Infarction; Male; Mice; Mic | 2010 |
Ischemia-induced stimulation of cerebral microvascular endothelial cell Na-K-Cl cotransport involves p38 and JNK MAP kinases.
Topics: Animals; Anthracenes; Blood-Brain Barrier; Brain; Brain Ischemia; Bumetanide; Cattle; Cell Hypoxia; | 2012 |